



FOR IMMEDIATE RELEASE

TransMolecular Announces Presentation of Data Confirming Anti-angiogenic Method-of-Action of TM601 at ARVO Annual Meeting

CAMBRIDGE, MA –April 30, 2009 – TransMolecular, Inc. today announced that new information on the anti-angiogenic method-of-action of TM601 will be presented in a poster session at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Fort Lauderdale, FL, being held May 3-7, 2009. TM601 is a novel, wholly synthetic peptide found to have robust anti-angiogenic activity in neovascular diseases, including ophthalmic disease and cancer.

Poster # 1164/D1126 is titled, "TM601, a Peptide That Binds Annexin A2, Causes Regression of Choroidal Neovascularization (CNV)," and will be presented on Sunday, May 3, 2009 from 2:45-4:30pm EDT. The presentation will take place in Exhibit Hall B/C as part of session number 160 on choroidal neovascularization.

About TM601

TM601 is a novel, wholly synthetic peptide found to have robust anti-angiogenic activity in neovascular diseases, including cancer and ophthalmic disease. Most recently, the effects of TM601 on the neovasculature have also been validated in animal models of ophthalmic disease, including wet age-related macular degeneration (AMD).

For oncology applications, TM601 is highly specific and selective in targeting both primary tumors and metastases in the periphery and in the central nervous system. TM601 has the unique properties of highly specific tumor cell binding, uptake and internalization. Clinical studies confirm that TM601 targets and binds to a receptor expressed on a wide range of tumor cells, but not on normal, healthy cells. TransMolecular is expanding the TM601 tumor-targeting platform to deliver a range of therapeutic agents, including novel and currently used chemotherapeutic agents, as well as RNAi molecules, to tumor cells.

About TransMolecular, Inc.

TransMolecular, Inc. is committed to discovering and developing novel therapeutic products that help patients combat cancer and neovascular diseases. TransMolecular's product pipeline is based on the TM601 platform, a novel synthetically-derived polypeptide, which has both highly specific tumor binding properties and anti-angiogenic therapeutic properties. More information can be found at www.transmolecular.com.

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with litigation, clinical trials, the regulatory approval process, reimbursement policies, commercialization of new technologies, intellectual property, and other factors.

Contacts:

TransMolecular:

Robert Radie
President and CEO
617-995-3050 x 303

Media:

Jennifer Greenleaf-Conrad
MacDougall Biomedical Communications
(781) 235-3060
jconrad@macbiocom.com

###